Measurable residual disease (MRD) can predict disease progression in patients who have acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML). A new review ...
It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
Measurable residual disease (MRD) is a critical diagnostic tool that predicts disease progression and is increasingly used as an important end point to monitor disease status and evaluate novel ...
The FDA's complete response letter for Dasynoc was due to manufacturing issues, delaying its approval for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) treatment. Dasynoc, a ...
FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a ...
STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company's first ...
ROCKVILLE, Md. and SUZHOU, China, Nov. 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results